Filing Details
- Accession Number:
- 0000899243-20-018847
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-09 18:48:00
- Reporting Period:
- 2020-07-07
- Accepted Time:
- 2020-07-09 18:48:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1701108 | Spero Therapeutics Inc. | SPRO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1720974 | Ankit Mahadevia | C/O Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14Th Floor Cambridge MA 02139 | Ceo And President | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-07-07 | 754 | $5.90 | 66,571 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-07-07 | 754 | $14.25 | 65,817 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-07-09 | 2,293 | $5.90 | 68,110 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-07-09 | 2,293 | $14.31 | 65,817 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-07-07 | 754 | $0.00 | 754 | $5.90 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2020-07-09 | 2,293 | $0.00 | 2,293 | $5.90 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 521,875 | 2027-07-05 | No | 4 | M | Direct | |
| 519,582 | 2027-07-05 | No | 4 | M | Direct |
Footnotes
- All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 3,047 shares).
- Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.285 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.37 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Billionaire Hedge Funds
